DK3236991T3 - Fgf21-derivater og anvendelser deraf - Google Patents
Fgf21-derivater og anvendelser deraf Download PDFInfo
- Publication number
- DK3236991T3 DK3236991T3 DK15817847.5T DK15817847T DK3236991T3 DK 3236991 T3 DK3236991 T3 DK 3236991T3 DK 15817847 T DK15817847 T DK 15817847T DK 3236991 T3 DK3236991 T3 DK 3236991T3
- Authority
- DK
- Denmark
- Prior art keywords
- applications
- fgf21 derivatives
- fgf21
- derivatives
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title 1
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14199935 | 2014-12-23 | ||
| PCT/EP2015/080969 WO2016102562A1 (en) | 2014-12-23 | 2015-12-22 | Fgf21 derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3236991T3 true DK3236991T3 (da) | 2019-08-26 |
Family
ID=52130150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15817847.5T DK3236991T3 (da) | 2014-12-23 | 2015-12-22 | Fgf21-derivater og anvendelser deraf |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9744213B2 (enExample) |
| EP (1) | EP3236991B1 (enExample) |
| JP (1) | JP6727210B2 (enExample) |
| KR (1) | KR102427527B1 (enExample) |
| CN (1) | CN107108709B (enExample) |
| AR (1) | AR103246A1 (enExample) |
| AU (1) | AU2015371056B2 (enExample) |
| DK (1) | DK3236991T3 (enExample) |
| ES (1) | ES2742503T3 (enExample) |
| HK (1) | HK1246156B (enExample) |
| HR (1) | HRP20191292T1 (enExample) |
| HU (1) | HUE044783T2 (enExample) |
| IL (1) | IL252438B (enExample) |
| MX (1) | MX377044B (enExample) |
| MY (1) | MY181181A (enExample) |
| PL (1) | PL3236991T3 (enExample) |
| PT (1) | PT3236991T (enExample) |
| RS (1) | RS59154B1 (enExample) |
| RU (1) | RU2729011C2 (enExample) |
| SA (1) | SA517381673B1 (enExample) |
| SI (1) | SI3236991T1 (enExample) |
| TW (2) | TWI708781B (enExample) |
| WO (1) | WO2016102562A1 (enExample) |
| ZA (1) | ZA201703768B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102433503B1 (ko) | 2016-05-24 | 2022-08-18 | 노보 노르디스크 에이/에스 | Mic-1 화합물 및 이것의 사용 |
| CN106421753A (zh) * | 2016-10-19 | 2017-02-22 | 哈尔滨医科大学 | 重组人成纤维细胞生长因子‑21在制备预防和治疗缺血性心律失常药物中的应用 |
| TWI710377B (zh) * | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Ｍｉｃ－１化合物及其用途 |
| WO2019043457A2 (en) | 2017-09-04 | 2019-03-07 | 89Bio Ltd. | CONJUGATES OF MUTANT PEPTIDE FGF-21 AND USES THEREOF |
| KR20210027426A (ko) | 2018-07-03 | 2021-03-10 | 브리스톨-마이어스 스큅 컴퍼니 | Fgf21 제제 |
| US11427623B1 (en) | 2019-05-28 | 2022-08-30 | 89Bio Ltd. | Methods of treatment using mutant FGF-21 peptide conjugates |
| CN113728013B (zh) | 2020-01-11 | 2022-06-14 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
| EP4089108A1 (en) | 2021-05-11 | 2022-11-16 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| US20240279297A1 (en) | 2021-05-11 | 2024-08-22 | Cytoki Pharma Aps | Therapeutic derivatives of interleukin-22 |
| KR102631925B1 (ko) * | 2021-06-10 | 2024-02-01 | 토드제약 주식회사 | 신규 fgf21 변이체 개발 및 이의 생산기법과 용도 |
| WO2023284822A1 (en) * | 2021-07-14 | 2023-01-19 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion polypeptides for metabolic disorders |
| JP2024531980A (ja) * | 2021-09-08 | 2024-09-03 | リートー ラボラトリーズ カンパニー リミテッド | Ｆｇｆ２１変異タンパク質及びその応用 |
| MA71385A (fr) | 2022-07-08 | 2025-04-30 | Novo Nordisk A/S | Composés isvd hautement puissants capables de remplacer fviii(a) |
| US12098400B2 (en) | 2022-07-08 | 2024-09-24 | Novo Nordisk A/S | Highly potent ISVD compounds capable of substituting for FVIII(A) |
| AR132255A1 (es) | 2023-03-30 | 2025-06-11 | Novo Nordisk As | Compuestos de fusión y usos de estos |
| CN121194798A (zh) * | 2023-05-12 | 2025-12-23 | 诺和诺德股份有限公司 | 长效生长激素受体拮抗剂及其用途 |
| KR20250039299A (ko) | 2023-09-11 | 2025-03-20 | 노보 노르디스크 에이/에스 | 항-il-6 도메인 항체 |
| CN118307684B (zh) * | 2024-06-11 | 2024-10-18 | 北京志道生物科技有限公司 | 一种经脂肪酸链修饰的glp-1-fgf21融合蛋白及其制备方法和应用 |
| WO2026012311A1 (zh) * | 2024-07-08 | 2026-01-15 | 浙江道尔生物科技有限公司 | Fgf21衍生物及其用途 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| WO2003011213A2 (en) | 2001-07-30 | 2003-02-13 | Eli Lilly And Company | Method for treating diabetes and obesity |
| EP1329227A1 (en) | 2002-01-22 | 2003-07-23 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells |
| ES2371072T3 (es) | 2003-06-12 | 2011-12-27 | Eli Lilly And Company | Proteínas de fusión análogas de glp-1. |
| EP1670515A2 (en) | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| TW200522976A (en) | 2003-09-19 | 2005-07-16 | Novo Nordisk As | Novel plasma protein affinity tags |
| EP2270163A1 (en) | 2003-12-10 | 2011-01-05 | Eli Lilly and Company | Muteins of fibroblast growth factor 21 |
| CN101665538A (zh) | 2003-12-18 | 2010-03-10 | 诺沃挪第克公司 | 与白蛋白样物质相连的新glp-1类似物 |
| WO2005091944A2 (en) | 2004-03-17 | 2005-10-06 | Eli Lilly And Company | Glycol linked fgf-21 compounds |
| PL1751184T3 (pl) | 2004-05-13 | 2010-02-26 | Lilly Co Eli | Białka fuzyjne FGF-21 |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| ES2542228T3 (es) | 2004-07-08 | 2015-08-03 | Novo Nordisk A/S | Marcas de prolongación polipeptídica que comprenden un resto de tetrazol |
| EP1789443A1 (en) | 2004-09-02 | 2007-05-30 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| BRPI0514790A (pt) | 2004-09-02 | 2008-06-24 | Lilly Co Eli | muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano |
| EP1814573B1 (en) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| JP2008522617A (ja) | 2004-12-14 | 2008-07-03 | イーライ リリー アンド カンパニー | 線維芽細胞成長因子２１の突然変異タンパク質 |
| EP1846019A2 (en) | 2005-01-21 | 2007-10-24 | Eli Lilly And Company | Method for treating cardiovascular disease |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US20100022446A1 (en) | 2007-01-18 | 2010-01-28 | Novo Nordisk A/S | Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity |
| CA2682147C (en) | 2007-03-30 | 2017-08-08 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
| SI2068909T1 (sl) | 2007-03-30 | 2012-09-28 | Ambrx Inc | Modificirani fgf-21 polipeptidi in njihova uporaba |
| US20110034373A1 (en) | 2007-08-03 | 2011-02-10 | Eli Lilly And Company | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
| US20100261637A1 (en) | 2007-09-05 | 2010-10-14 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| CN100587073C (zh) | 2008-03-24 | 2010-02-03 | 吉林农大生物反应器工程有限公司 | 人成纤维细胞生长因子-21的重组表达 |
| SG193860A1 (en) * | 2008-06-04 | 2013-10-30 | Amgen Inc | Fgf21 mutants and uses thereof |
| NZ592009A (en) * | 2008-10-10 | 2012-11-30 | Amgen Inc | Fgf21 mutants and uses thereof |
| WO2010065439A1 (en) | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
| CN102361647B (zh) * | 2009-01-23 | 2018-02-16 | 诺沃-诺迪斯克有限公司 | 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用 |
| AU2010246038A1 (en) | 2009-05-05 | 2011-12-01 | Amgen Inc. | FGF21 mutants and uses thereof |
| BRPI1011404B1 (pt) | 2009-05-05 | 2022-05-03 | Amgen Inc | Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira |
| US20120035099A1 (en) | 2009-06-11 | 2012-02-09 | Novo Nordisk A/S | Fgf21 analogues and derivatives |
| CN102802657A (zh) | 2009-06-11 | 2012-11-28 | 诺沃-诺迪斯克有限公司 | 用于治疗2型糖尿病的glp-1和fgf21组合 |
| JP2013533227A (ja) * | 2010-06-08 | 2013-08-22 | ノヴォ ノルディスク アー／エス | Ｆｇｆ２１類似体および誘導体 |
| CN103415300B (zh) * | 2010-07-20 | 2018-02-23 | 诺沃—诺迪斯克有限公司 | N‑末端修饰的fgf21化合物 |
| WO2013033452A2 (en) * | 2011-08-31 | 2013-03-07 | Amgen Inc. | Method of treating or ameliorating type 1 diabetes using fgf21 |
| MX2015002985A (es) * | 2012-09-07 | 2015-06-22 | Sanofi Sa | Proteinas de fusion para el tratamiento de un sindrome metabolico. |
| MX383664B (es) * | 2012-12-27 | 2025-03-14 | Ngm Biopharmaceuticals Inc | Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares. |
-
2015
- 2015-12-22 RS RSP20191106 patent/RS59154B1/sr unknown
- 2015-12-22 JP JP2017533789A patent/JP6727210B2/ja active Active
- 2015-12-22 TW TW108144310A patent/TWI708781B/zh active
- 2015-12-22 PL PL15817847T patent/PL3236991T3/pl unknown
- 2015-12-22 HK HK18105587.8A patent/HK1246156B/en unknown
- 2015-12-22 SI SI201530859T patent/SI3236991T1/sl unknown
- 2015-12-22 RU RU2017125050A patent/RU2729011C2/ru active
- 2015-12-22 HU HUE15817847 patent/HUE044783T2/hu unknown
- 2015-12-22 MY MYPI2017701848A patent/MY181181A/en unknown
- 2015-12-22 WO PCT/EP2015/080969 patent/WO2016102562A1/en not_active Ceased
- 2015-12-22 ES ES15817847T patent/ES2742503T3/es active Active
- 2015-12-22 AR ARP150104256A patent/AR103246A1/es active IP Right Grant
- 2015-12-22 DK DK15817847.5T patent/DK3236991T3/da active
- 2015-12-22 EP EP15817847.5A patent/EP3236991B1/en active Active
- 2015-12-22 AU AU2015371056A patent/AU2015371056B2/en active Active
- 2015-12-22 KR KR1020177017682A patent/KR102427527B1/ko active Active
- 2015-12-22 CN CN201580069436.9A patent/CN107108709B/zh active Active
- 2015-12-22 TW TW104143111A patent/TWI681966B/zh active
- 2015-12-22 PT PT15817847T patent/PT3236991T/pt unknown
- 2015-12-22 MX MX2017007458A patent/MX377044B/es active IP Right Grant
- 2015-12-22 HR HRP20191292TT patent/HRP20191292T1/hr unknown
-
2017
- 2017-03-08 US US15/453,617 patent/US9744213B2/en active Active
- 2017-05-22 IL IL252438A patent/IL252438B/en unknown
- 2017-06-01 ZA ZA2017/03768A patent/ZA201703768B/en unknown
- 2017-06-06 SA SA517381673A patent/SA517381673B1/ar unknown
- 2017-07-07 US US15/643,543 patent/US9895417B2/en active Active
- 2017-12-21 US US15/849,920 patent/US10124039B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20230014I1 (fi) | Foslevodopa ja foskarbidopa | |
| IL285286A (en) | Transposase polypeptides and uses thereof | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| DK3157552T3 (da) | Syntac-polypeptider og anvendelser deraf | |
| IL280863A (en) | Autotaxin inhibitors and uses thereof | |
| DK3412302T3 (da) | Modificerede fgf-21-polypeptider og anvendelser deraf | |
| DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
| DK3210977T3 (da) | Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf | |
| HRP20181742T1 (hr) | Hidroksialkil-supstituirani derivati feniltriazola i njihova uporaba | |
| DK3354282T3 (da) | Glycan-terapeutiske midler og relaterede fremgangsmåder deraf | |
| DK3229838T3 (da) | Anti-C10orf54-antistoffer og anvendelser deraf | |
| EP3205103C0 (en) | INTER AND INTRA UNIFICATION BLOCK COPY | |
| DK3212255T3 (da) | Selvorienterende sprøjte og sprøjtegrænseflade | |
| DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
| DK3015526T3 (da) | Hydrofluorolefinbaseret sammensætning og anvendelse deraf | |
| DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
| DK3209773T3 (da) | Prolintolerante tripeptidylpeptidaser og anvendelser deraf | |
| DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
| SI3236991T1 (sl) | Derivati FGF21 in njihova uporaba | |
| DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
| DK3337506T3 (da) | Kombinationer og anvendelser deraf | |
| DK3321279T3 (da) | Exenatidmodificeringsmiddel og anvendelse deraf | |
| DK3417058T3 (da) | Sortase-modificerede molekyler og anvendelser deraf | |
| DK3365321T3 (da) | Solabegron-zwitterion og anvendelser deraf | |
| SI3143018T1 (sl) | Derivati karboksamida |